Translational Research

  1. Can Kinetics Provide Detailed Information About Binding Interactions? 2/17/2022

    See the potential value kinetics brings to deepen the understanding of biological processes.

  2. Is Evaporation Important For Optical Biosensors? 2/17/2022

    If your sample is open to evaporation effects causing your concentration to change, will your data, and potentially your conclusions, be unreliable?

  3. LC/MS Method For Measurement In Human Plasma 2/17/2025

    According to the researchers, this plasma-based measurement has the potential to serve as a critical pharmacodynamic biomarker, facilitating the assessment of novel therapeutic approaches.

  4. Is The Sensitivity Of Optical Biosensors Important? 2/17/2022

    Explore why the sensitivity of optical biosensors is important for not just small molecules or fragment-based interactions but also for larger molecular entities.

  5. Analytics & Assays: Defining mRNA Therapeutic Impurities Early & Often 12/5/2023

    mRNA therapeutics present a whole new safety paradigm not seen in vaccine applications. In this segment, Combined Therapeutics CSO Thomas Van Cott, Ph.D. and Omega Therapeutics Executive Director, Process Development and Analytical Sciences Jeff Atkinson, Ph.D. address the nuances of mRNA therapeutic analytics and assays.

  6. A Derivatization-Free LCMS Assay For 4β-hydroxycholesterol 1/23/2025

    Learn about a novel LCMS assay for 4β-hydroxycholesterol, a key biomarker for CYP3A activity. This derivatization-free method offers a faster and more efficient approach for clinical studies.

  7. LC/MS/MS Analysis Of Coproporphyrin 1, Coproporphyrin 3 In Human Plasma 2/17/2025

    This innovative approach holds promise for reducing the need for extensive clinical drug-drug interaction studies, potentially streamlining the drug development process.

  8. How To Best Optimize mRNA Production Workflows 4/11/2023

    Multiple steps in the mRNA manufacturing process can appear more complex than they have to be. Learn how to simplify your approach and produce the best possible mRNA vaccines and therapeutics.